Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2,509 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.
Ghisoli M, Barve M, Mennel R, Lenarsky C, Horvath S, Wallraven G, Pappen BO, Whiting S, Rao D, Senzer N, Nemunaitis J. Ghisoli M, et al. Mol Ther. 2016 Aug;24(8):1478-83. doi: 10.1038/mt.2016.86. Epub 2016 Apr 25. Mol Ther. 2016. PMID: 27109631 Free PMC article.
Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.
Ghisoli M, Rutledge M, Stephens PJ, Mennel R, Barve M, Manley M, Oliai BR, Murphy KM, Manning L, Gutierrez B, Rangadass P, Walker A, Wang Z, Rao D, Adams N, Wallraven G, Senzer N, Nemunaitis J. Ghisoli M, et al. J Pediatr Hematol Oncol. 2017 May;39(4):e183-e186. doi: 10.1097/MPH.0000000000000822. J Pediatr Hematol Oncol. 2017. PMID: 28338569
Assessment of intravenous pbi-shRNA PDX1 nanoparticle (OFHIRNA-PDX1) in yucatan swine.
Jay CM, Ruoff C, Kumar P, Maass H, Spanhel B, Miller M, Arrington A, Montalvo N, Gresham V, Rao DD, Evans C, Wang Z, Brunicardi FC, Liu SH, Zhou G, Senzer N, Nemunaitis J, King L, Weeks B, Clubb FJ, Fossum TW, Maples PB. Jay CM, et al. Cancer Gene Ther. 2013 Dec;20(12):683-9. doi: 10.1038/cgt.2013.68. Epub 2013 Nov 29. Cancer Gene Ther. 2013. PMID: 24287722
Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference.
Rao DD, Maples PB, Senzer N, Kumar P, Wang Z, Pappen BO, Yu Y, Haddock C, Jay C, Phadke AP, Chen S, Kuhn J, Dylewski D, Scott S, Monsma D, Webb C, Tong A, Shanahan D, Nemunaitis J. Rao DD, et al. Cancer Gene Ther. 2010 Nov;17(11):780-91. doi: 10.1038/cgt.2010.35. Epub 2010 Jul 2. Cancer Gene Ther. 2010. PMID: 20596090
Proof concept for clinical justification of network mapping for personalized cancer therapeutics.
Nemunaitis J, Senzer N, Khalil I, Shen Y, Kumar P, Tong A, Kuhn J, Lamont J, Nemunaitis M, Rao D, Zhang YA, Zhou Y, Vorhies J, Maples P, Hill C, Shanahan D. Nemunaitis J, et al. Cancer Gene Ther. 2007 Aug;14(8):686-95. doi: 10.1038/sj.cgt.7701057. Epub 2007 Jun 1. Cancer Gene Ther. 2007. PMID: 17541424
Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform.
Wu J, Liu S, Yu J, Zhou G, Rao D, Jay CM, Kumar P, Sanchez R, Templeton N, Senzer N, Maples P, Nemunaitis J, Brunicardi FC. Wu J, et al. Cancer Gene Ther. 2014 Feb;21(2):48-53. doi: 10.1038/cgt.2013.84. Epub 2014 Jan 24. Cancer Gene Ther. 2014. PMID: 24457987 Review.
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.
Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N, Rao DD, Wang Z, Jay CM, Pappen BO, Wallraven G, Brunicardi FC, Shanahan DM, Maples PB, Nemunaitis J. Senzer N, et al. Mol Ther. 2012 Mar;20(3):679-86. doi: 10.1038/mt.2011.269. Epub 2011 Dec 20. Mol Ther. 2012. PMID: 22186789 Free PMC article. Clinical Trial.
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.
Barve M, Wang Z, Kumar P, Jay CM, Luo X, Bedell C, Mennel RG, Wallraven G, Brunicardi FC, Senzer N, Nemunaitis J, Rao DD. Barve M, et al. Mol Ther. 2015 Jun;23(6):1123-1130. doi: 10.1038/mt.2015.14. Epub 2015 Jan 26. Mol Ther. 2015. PMID: 25619726 Free PMC article. Clinical Trial.
2,509 results
Jump to page